NGS Panel Validation Using Controlled Variant Allele Fractions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for validating next-generation sequencing (NGS) panels face challenges in accurately assessing sensitivity and specificity, particularly for variants with low allele frequencies, and lack precise detection of indels and amplifications/deletions, due to issues like allelic bias and detection pipeline variability, necessitating improved validation standards.
Innovation Solution
A composition and kit using homozygote DNA and control genomic DNA at various dilution ratios to validate NGS panels, analyzing false negatives, false positives, and limit of detection through Ho-N, He-N, and N-N pair alleles, with methods to derive stringency cutoffs for enhanced specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If HapMap cell line mixtures are used for validation, then sensitivity and specificity can be evaluated, but alleles with VAF less than 5% cannot be detected and insufficient alleles are available for accurate sensitivity measurement
Solution Approach 1:
The patent changes the composition parameters of the DNA mixture by using isogenic cell lines with precisely controlled variant allele fractions. Instead of using HapMap cell lines with natural variation, the invention creates custom mixtures with defined VAFs including 1%, 2.5%, 5%, 10%, 20%, 40%, and 80%, enabling accurate sensitivity measurement across the full range of clinically relevant allele frequencies.
Solution Approach 2:
The patent segments the validation process by creating multiple distinct DNA mixture samples, each with a specific variant allele fraction. This segmentation allows independent evaluation of detection sensitivity at each VAF level, providing granular measurement of panel performance across different allele frequencies rather than a single aggregate metric.
2Adaptability or versatility
If multiple HapMap cell lines are mixed to create DNA pools, then variant diversity is achieved, but mixing errors occur and precise control of variant allele fraction is lost
Solution Approach 1:
The patent uses isogenic cell lines that are genetic copies except for the specific variant of interest. This copying approach maintains genetic uniformity while introducing a controlled variation, eliminating the diversity issues that arise from mixing unrelated HapMap cell lines while preserving the ability to study variant detection.
Solution Approach 2:
The patent performs preliminary characterization of cell line genotypes before mixing to ensure precise control of variant allele fractions. By pre-validating the genetic composition of each cell line and calculating the expected VAF based on mixing ratios, the invention achieves manufacturing precision without requiring complex mixing procedures.
3Productivity
If down-sampled coverage is reduced to decrease cost or increase throughput, then processing efficiency improves, but detection sensitivity for low VAF alleles deteriorates
Solution Approach 1:
The patent applies partial action by evaluating panel performance at multiple down-sampled coverage levels (100x, 300x, 500x, 1000x) rather than requiring full sequencing depth for all samples. This allows identification of the minimum coverage needed to achieve clinically acceptable sensitivity, optimizing the balance between productivity and measurement precision.
Data Source
AI summary
The present invention relates to: a composition for validating next generation sequencing (NGS) panels, comprising homozygote DNA and control genomic DNA; a kit for validation of NGS panels, comprising the composition; a validation method for NGS panels through the analysis of false negative variants, limit of detection, and false positive variants; and a method for providing information to enhance the specificity of NGS panels. In particular, the validation method of the present invention enables the objective analysis of the frequency of false negative variants, the frequency of false positive variants, and the limit of detection for NGS panels, making it effectively usable in the validation of NGS panels.